secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001683168-23-003010
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals appoints Bettina Cockroft, M.D., M.B.A. to Board of Directors
--------------------------------------------------------------------------------

- Appointed Bettina Cockroft as independent director effective May 3, 2023; no committee assignments at this time.
- Granted ten-year option for 8,300 shares at $1.67, vesting monthly over 36 months.
- Cockroft is SVP/CMO of Sangamo Therapeutics, with over 30 years biopharma experience.
- Standard non-employee director compensation applies, as described in prior SEC filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823003010/0001683168-23-003010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823003010/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-003010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer